Who We Are
SJC Bio has licensed foundational biomaterials technology from Vanderbilt University, building upon more than a decade of research in resorbable polymer-ceramic composite systems. OsseoCem™ is the company’s first dental product developed from this platform.
Why It Matters
Most bone graft materials function primarily as biologic scaffolds — they are not load-bearing and provide limited mechanical stability at placement. Particulate grafts rely on membranes and technique to maintain shape, and final geometry and stability are typically achieved only after months of bone ingrowth and remodeling
OsseoCem reverses this order by setting into a cohesive scaffold that provides immediate site stability and defined geometry at placement, while the biology progresses naturally over time.
While OsseoCem represents the company’s first clinical application, SJC Bio’s biomaterials platform is designed to support future regenerative technologies across dental and craniofacial surgery.
How We Execute
SJC Bio operates a capital-efficient distributed development model, leveraging specialized CRO partners and expert consultants as integrated development teams.